RTID-09. A RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF ENZASTAURIN ADDED TO TEMOZOLOMIDE DURING AND FOLLOWING RADIATION THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS WHO POSSESS THE NOVEL BIOMARKER, DGM1

Authors: Nicholas Butowski, Ying Mao, Wilson Wu, Wen Luo, Lan Ge, Daniel Pertschuk, Theresa Dewitt, Isabel Han, Thomas Heineman

Published: 2020-12-04

DOI: 10.1093/neuonc/noaa215.814

Source: Full article